Arbor's Bid For XenoPort Likely Driven By Effort To Grow Horizant
This article was originally published in The Pink Sheet Daily
With minimal unencumbered pipeline assets to offer, XenoPort's value to Arbor apparently lies in positive sales trends for the modest-selling restless legs and postherpetic neuralgia drug.
You may also be interested in...
Ireland's Jazz pays $1.5bn to acquire Celator and its hotly anticipated leukemia drug, Vyxeos; Spero takes over antibacterial program out-licensed by Vertex; Novartis to copromote Eisai's Lenvima.
Deerfield Management, the $3.5 billion health care hedge fund, is aggressively expanding its investments in private life sciences companies. As many VCs continue to struggle raising new funds Deerfield hopes its shift, combined with a flexible, research-driven approach to investing and a new involvement in the civic and academic activities shaping the sector, will secure its position as a top health care financier.
The California biotech likely to get a lifeline, while GSK will benefit from incremental revenues, but the market, including payers, has to yet to be educated.